ReviewImmune network2022
Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.
Review in Immune network, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Review
- Modeling the Application of Chimeric Antigen Receptor T Cell Therapy to Eliminate Alloantibodies in Mice.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Bibliometric analysis of global research hotspots in ovarian cancer immunotherapy from 2014 to 2024 using CiteSpace.Human vaccines & immunotherapeutics · 2025Article
- Cellular therapies in rheumatic and musculoskeletal diseases.Journal of translational autoimmunity · 2025Review
- Biological functions and therapeutic applications of human mucosal-associated invariant T cells.Journal of biomedical science · 2025Review
- Review
- CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.International journal of molecular sciences · 2024Review
- Mitochondria Activity and CXCR4 Collaboratively Promote the Differentiation of CD11cImmune network · 2024Article
- Bridging the gender gap in autoimmunity with T-cell-targeted biomaterials.Current opinion in biotechnology · 2024Review
- The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment.Frontiers in pharmacology · 2024Review
- Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches.International journal of molecular sciences · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.